Related Experiment Video
Updated: Jan 20, 2026

Long-term Culture of Human Breast Cancer Specimens and Their Analysis Using Optical Projection Tomography
Published on: July 29, 2011
Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
William B Kietzman1, Garrett T Graham1, Virginie Ory1
1Department of Oncology, Georgetown University, Washington, District of Columbia.
Abstract:
CDK4/6 inhibitors are used in the treatment of advanced estrogen receptor (ER)(+) breast cancer. Their efficacy in ER(-) and early-stage breast cancer is currently under investigation. Here, we show that palbociclib, a CDK4/6 inhibitor, can inhibit both progression of ductal carcinoma in situ (DCIS) and growth of invasive disease in both an ER(-) basal breast cancer model (MCFDCIS) and an ER(+) luminal model (MCF7 intraductal injection). In MCFDCIS cells, palbociclib repressed cell-cycle gene expression, inhibited proliferation, induced senescence, and normalized tumorspheres formed in Matrigel while the formation of acini by normal mammary epithelial cells (MCF10A) was not affected. Palbociclib treatment of mice with MCFDCIS tumors inhibited their malignant progression and reduced proliferation of invasive lesions. Transcriptomic analysis of the tumor and stromal cell compartments showed that cell cycle and senescence genes, and MUC16, an ovarian cancer biomarker gene, were repressed during treatment. Knockdown of MUC16 in MCFDCIS cells inhibited proliferation of invasive lesions but not progression of DCIS. After cessation of palbociclib treatment genes associated with differentiation, for example, P63, inflammation, IFNγ response, and antigen processing and presentation remained suppressed in the tumor and surrounding stroma. We conclude that palbociclib can prevent progression of DCIS and is antiproliferative in ER(-) invasive disease mediated in part via MUC16. Lasting effects of CDK4/6 inhibition after drug withdrawal on differentiation and the immune response could impact the approach to treatment of early-stage ER(-) breast cancer.
Insights
Palbociclib, a CDK4/6 inhibitor, prevents ductal carcinoma in situ progression and inhibits ER(-) invasive breast cancer growth, partly via MUC16. Lasting effects may influence early-stage treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- CDK4/6 inhibitors are established treatments for advanced ER(+) breast cancer.
- Their role in ER(-) and early-stage breast cancer remains under investigation.
Purpose of the Study:
- To investigate the efficacy of palbociclib, a CDK4/6 inhibitor, in both ER(-) and ER(+) breast cancer models, including ductal carcinoma in situ (DCIS) and invasive disease.
- To explore the molecular mechanisms underlying palbociclib's effects, including gene expression changes and the role of MUC16.
Main Methods:
- Utilized ER(-) (MCFDCIS) and ER(+) (MCF7) breast cancer models in vitro and in vivo.
- Administered palbociclib and assessed tumor progression, proliferation, and senescence.
- Performed transcriptomic analysis of tumor and stromal compartments.
- Investigated the role of MUC16 through gene knockdown experiments.
Main Results:
- Palbociclib inhibited DCIS progression and invasive disease growth in both ER(-) and ER(+) models.
- Palbociclib repressed cell cycle genes, induced senescence, and normalized tumorspheres.
- Transcriptomic analysis revealed repression of cell cycle, senescence genes, and MUC16.
- MUC16 knockdown inhibited invasive lesion proliferation but not DCIS progression.
- Post-treatment, differentiation and immune response genes remained suppressed.
Conclusions:
- Palbociclib prevents DCIS progression and exhibits antiproliferative effects in ER(-) invasive breast cancer, partly mediated by MUC16.
- Sustained effects on differentiation and immune response after drug withdrawal may impact early-stage ER(-) breast cancer treatment approaches.
Related Concept Videos
Feedback Inhibition
Long-term Depression
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Framing Effects
Enzyme Inhibition
Biological Effects of Radiation

